Purdue Pharma judge rejects call to halt opioid deal
New Delhi: Purdue Pharma has defeated a request to pause the implementation of its reorganization plan that provides legal protections to the Sackler family members who owned it.
U.S. District Judge Colleen McMahon in Manhattan issued a brief ruling on Wednesday evening denying without prejudice a motion from the Department of Justice's bankruptcy watchdog, the U.S. Trustee, to stay a bankruptcy judge's September order approving Purdue's plan and underlying opioid litigation settlement while the appeals process is playing out.
However, McMahon said her ruling is conditioned upon an agreement from the OxyContin maker that it will not attempt to argue that appeals of the order are "equitably moot," or effectively irrelevant, down the road.
Purdue attorney Marshall Huebner of Davis Polk & Wardwell indicated during a hearing on Tuesday that his team would be willing to make that stipulation.
The U.S. Trustee has made the same request to stay the plan's implementation to U.S. Bankruptcy Judge Robert Drain, who approved the plan in September. A hearing on that request is set for Nov. 9.
Read also: Drugmaker Endo to pay USD 35 million to settle opoid claims by Tennessee counties
The case is In re Purdue Pharma LP, U.S. District Court, Southern District of New York, No. 21-07966.
For Purdue: Marshall Huebner, Benjamin Kaminetzky, Timothy Graulich, Eli Vonnegut and James McClammy of Davis Polk & Wardwell; and Paul Breene, Ann Kramer, Anthony Crawford and Lisa Szymanski of Reed Smith
Read also: Opioid Crisis: OxyContin maker Purdue Pharma pleads guilty to criminal charges
